Opening Symptom Science and Cancer Survivors: Lessons Learned, Opportunities, and Challenges
Symptom Science and Cancer Survivors: Lessons Learned, Opportunities, and Challenges
- Length
- 1 h 2 min
- Level
- Research
- Recorded
- Yale University2024
Chapter 1 of 9: Before the lecture
Symptom science in cancer survivors connects the lasting effects of treatment to measurable biology and individual risk. Ganz, speaking at Yale Cancer Center Grand Rounds, starts from the Wilson and Cleary model of health-related quality of life. She argues that symptom status belongs inside that model rather than in a separate domain. Baseline and follow-up data from the Breast Cancer Prevention Trial and NSABP B-35 show which symptoms cluster and persist after tamoxifen, raloxifene or anastrozole. Later sections tie fatigue and cognitive complaints to age, BMI, prior depression, proinflammatory cytokines and cytokine gene variants, then turn to young adult and metastatic survivors.

Your comment is kept while you sign up.Sign in
Ganz links patient-reported symptoms in breast cancer prevention trials to inflammatory cytokines and host factors.
Symptom science in cancer survivors connects the lasting effects of treatment to measurable biology and individual risk. Ganz, speaking at Yale Cancer Center Grand Rounds, starts from the Wilson and Cleary model of health-related quality of life. She argues that symptom status belongs inside that model rather than in a separate domain. Baseline and follow-up data from the Breast Cancer Prevention Trial and NSABP B-35 show which symptoms cluster and persist after tamoxifen, raloxifene or anastrozole. Later sections tie fatigue and cognitive complaints to age, BMI, prior depression, proinflammatory cytokines and cytokine gene variants, then turn to young adult and metastatic survivors.
Linking Clinical Variables With Health-Related Quality of Life: A Conceptual Model of Patient Outcomes
Base-Line Quality-of-Life Assessment in the National Surgical Adjuvant Breast And Bowel Project Breast Cancer Prevention Trial
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ with lumpectomy plus radiotherapy (NSABP B-35)
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
CA-Journal for Clinicians
Trends in the Number of Cancer Survivors Reporting Functional Limitation in the US, 1999 to 2018
Swain SM et al. N Engl J Med 2010;362:2053-2065
Bandos, et al., JNCI 2018
Sedrak, J Am Geriat Soc 2021
JCO Review Paper (2008)
Bower et al. JCO 2000; Bower et al. Psychosom Med 2002; Bower et al. Cancer 2006
Nature Reviews Clinical Oncology (2014)
This lecture
Talk 10 of 26 of Yale Cancer Center Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Cytokine Genetic Variations and Fatigue Among Patients With Breast Cancer (Bower et al., JCO, 2013)
Biotech's 14-18 trial
Do All Patients With Cancer Experience Fatigue? A Longitudinal Study of Fatigue Trajectories in Women With Breast Cancer (2021)
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care
Cost of Cancer in Adolescents and Young Adults in the United States: Results of the 2021 Report by Deloitte Access Economics
Estimation of the Number of Individuals Living With Metastatic Cancer in the United States
Lost in Transition Report
Systemic inflammation and cancer-related frailty: shifting the paradigm toward precision survivorship medicine